mCRPC Treatment Videos

177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor

October 31, 2019

Details

Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal

October 17, 2019

Details

A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor

October 14, 2019

Details

Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin

September 26, 2019

Details

Clinical Trial Treatment Options for Rare GU Malignancies - Bradley McGregor

September 12, 2019

Details

A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran

August 2, 2019

Details

Radium-223 in Clinical Practice - Phillip J. Koo

August 2, 2019

Details

Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal

June 11, 2019

Details

Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan

May 31, 2019

Details

The Changing Therapeutic Landscape of Prostate Cancer- Nicholas Vogelzang

May 12, 2019

Details

Improved Survival Outcomes of African America Men with mCRPC Treated with Sipuleucel-T - Kelvin Moses

April 23, 2019

Details

Treatment Decisions for Patients with Metastatic Castration-resistant Prostate Cancer: A Retrospective Study of Real-World Experience - Tia Higano

March 27, 2019

Details

The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

January 31, 2019

Details

Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava

January 28, 2019

Details

An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.

October 28, 2018

Details

Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad

October 11, 2018

Details

Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz

May 8, 2018

Details

Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

May 3, 2018

Details

UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin

January 6, 2018

Details

Sequencing and Combining CRPC Therapies: What Does the Future Hold? - Charles Ryan

November 10, 2017

Details

Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective

September 18, 2017

Details

Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

October 9, 2017

Details

STAMPEDE and LATITUDE Trials: Issues to Consider - Thomas Keane

August 1, 2017

Details

A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE

June 21, 2017

Details

Preliminary Data from the PROCEED Registry- Oliver Sartor

June 6, 2017

Details

Should AR-V7 Be Used As A Clnical Test? - Philip Kantoff

April 28, 2017

Details

AR-V7: What We Know, What We Think - Christopher Evans

April 27, 2017

Details

AR-V7 Testing in Clinical Practice: Not Ready for Prime Time - Tomasz Beer

April 27, 2017

Details

Treatment of M1 Disease No Local Treatment - Nicolas Mottet

April 19, 2017

Details

Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

April 19, 2017

Details

Managing the ‘Start’ and ‘Stop’ of Various Therapies for Treating CRPC Patients - Is Timing Everything?- Karim Fizazi

April 18, 2017

Details

When and What hormonal therapy to use for men with castration-sensitive/naive prostate cancer and isolated biochemical recurrence(M0) after radical treatment - Martin Gleave

April 12, 2017

Details

CRPC M0 and M1: Sequencing and Combination Therapy - Take home message - Ian Davis

April 12, 2017

Details

Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi

January 31, 2017

Details

Management of Chronic Pre-existing or Treatment-emergent Adverse Events of the “other" Systemic Therapies - Michael J. Morris

April 10, 2017

Details

Phil Kantoff on AR-V7: Ready for use in daily clinical decision making

March 14, 2017

Details

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan

February 9, 2017

Details

IMAAGEN Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on PSA in Patients with Non-Metastatic Castration-Resistant Prostate Cancer - Charles Ryan

July 28, 2016

Details

Abiraterone in Elderly Chemotherapy-Naive Patients with mCRPC - Charles Ryan

April 28, 2016

Details

Charles Ryan on mCRPC Treatment: Combination Therapy - Clinical Case

April 26, 2016

Details

Charles Ryan on mCRPC Treatment: When to Start Abiraterone?

April 26, 2016

Details

Assessment of Corticosteroid-Associated Adverse Events With Long Term Exposure to Low-Dose Prednisone Given With Abiraterone Acetate to mCRPC Patients - Charles Ryan

January 7, 2016

Details

Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer - Michael Cookson

April 1, 2016

Details

Peter Scardino on A Century of Progress in Urologic Cancers 1915-2015 - MSKCC

September 3, 2015

Details

Charles Ryan on Practical Considerations in the Use of Novel Hormone Agents in the Post-ADT Setting

August 17, 2015

Details

William Lowrance on AUA Guideline: Castration-resistant Prostate Cancer Update

May 19, 2015

Details

Journal Club: Final OS Analysis of COU-AA-302 - Abiraterone in mCRPC without Prior Chemo - Charles Ryan

March 27, 2015

Details

Radiographic Progression-free Survival as a Response Biomarker in mCRPC: COU-AA-302 Results - Charles Ryan

March 7, 2015

Details

Alicia Morgans on Transitions in Treating mCRPC: Abiraterone after Sipuleucel-T

February 21, 2015

Details

Selection of Systemic Therapy: Chemotherapy and Androgen Axis Agents - Evan Yu

March 11, 2015

Details

Lower Tumor Burden Patient with Progression after Sipuleucel-T, Treated with Abiraterone Acetate - Charles Ryan

January 16, 2015

Details

Thomas Keane on NCCN Guidelines Update - 2015

December 2, 2014

Details

Final OS Analysis of COU-AA-302 - Study of Abiraterone Acetate in mCRPC without Prior Chemo - Charles Ryan

October 28, 2014

Details

Understanding Antigen Spreading in Immunotherapy

August 6, 2014

Details

Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa

June 27, 2014

Details

The Art and Science of Treating Men with CRPC

June 11, 2014

Details

Final Analysis of Early Access Protocol with AA in mCRPC Patients

June 3, 2014

Details

PSMA Antibody Drug Conjugate in Taxane-treated mCRPC

April 14, 2014

Details

Potential Sequencing of Newer Agents for mCRPC

March 28, 2014

Details

Novel Hormonal Therapies

March 27, 2014

Details

State-of-the-Art Advanced Treatment Landscape

March 20, 2014

Details

Sequencing Therapy in Advanced PCa: Focus on Sip-T

March 16, 2014

Details

Treatment of Progressing mCRPC

March 11, 2014

Details

Oral Androgen Receptor Pathway Agents are Changing PCa+ Treatment

February 24, 2014

Details

Androgen Resistance - The Dream Team Research

February 7, 2014

Details

December 3, 2013

Details

Abiraterone Acetate: Evolving Treatment for Metastatic CRPC

November 23, 2013

Details

PSA Changes as a Surrogate for OS in Men with mCRPC

November 21, 2013

Details

The Changing Role of the Urologist

October 30, 2013

Details

Treatment of mCRPC Pre-chemotherapy

September 14, 2013

Details

Treatment of mCRPC

September 13, 2013

Details

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.